Navigation Links
If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
Date:2/11/2009

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from GlaxoSmithKline's Tykerb/Tyverb for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. This is particularly true in the second- and subsequent HER2-positive treatment lines which are currently its most vulnerable market segments.

The new report entitled HER2-Positive Breast Cancer: Oncologists Are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting also finds that Genentech/Roche/Chugai's pertuzumab in combination with Herceptin and Sanofi Aventis' Taxotere will become Decision Resources' proprietary clinical gold standard regimen for HER2-positive breast cancer by 2017. This will occur following its approval for the indication in combination with Herceptin and Taxotere in 2013.

"Based on surveys and interviews we conducted with U.S. and European oncologists, as well as comparative drug analysis using our proprietary drug comparator model, we concluded that pertuzumab will have competitive advantages in efficacy when used in combination with Herceptin and Taxotere versus using Herceptin and Taxotere alone," stated Niamh Murphy, Ph.D., analyst at Decision Resources.

About the Report

HER2-Positive Breast Cancer: Oncologists are Eager for Improvements in Overall Survival Compared with Trastuzumab in the Metastatic Setting is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:
    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
2. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
3. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
4. Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement
5. A Newly Approved CMS Medicare Package Expands Reimbursement Coverage for Telehealth Originating Sites Beginning January 1, 2009
6. CSL Behring Receives FDA Approval of RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
7. Alliance for Pediatric Quality Supports New ANSI-Approved Standard for Child Health Passed by HL7
8. New Roche Dual Target HIV-1 Test Approved for Use in European Union
9. The First Treatment Specifically Approved for Huntingtons Disease Patients is Now Available in the United States
10. Bayer Marketing Two Unapproved Aspirin Products: FDA
11. Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional ... Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to extend ... , The demand for supplemental training related to pain management has surged dramatically ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  LifeVac, the revolutionary device ... in the Emergency Response Training and Support Services (ERTSS) ... to have LifeVac become part of the ERTSS mission ... and CEO of LifeVac. "Having an established network of ... effectively will help leverage our efforts to spread LifeVac,s ...
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... , Dec. 2, 2016 In the ... sources apart from those derived from C. sativa, the ... Universita` di Napoli Federico II , the Universita` ... the first comprehensive, critical, integrated and unified inventory of ... article focuses on the remarkable chemical and structural ...
Breaking Medicine Technology: